|
|
|
Fiscal Period: December
|
2019 |
2020 |
2021 |
2022 |
2023 |
| Capitalization1 |
3 720 | 8 087 | 5 879 | - | - |
| Entreprise Value (EV)1 |
3 720 | 8 087 | 5 576 | 5 675 | 5 717 |
| P/E ratio |
-29,6x | -53,3x | -23,6x | -25,3x | -25,5x |
| Yield |
- | - | - | - | - |
| Capitalization / Revenue |
43,7x | 82,2x | 39,0x | 26,7x | 18,3x |
| EV / Revenue |
43,7x | 82,2x | 37,0x | 25,8x | 17,8x |
| EV / EBITDA |
-64,7x | -67,6x | -27,3x | -32,0x | -56,4x |
| Price to Book |
3,62x | - | 9,22x | 12,2x | 11,1x |
| Nbr of stocks (in thousands) |
124 339 | 136 772 | 139 220 | - | - |
| Reference price (USD) |
29,9 | 59,1 | 42,2 | 42,2 | 42,2 |
| Last update |
02/26/2020 | 02/24/2021 | 02/25/2021 | 02/25/2021 | 02/25/2021 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Net sales1 |
55,7 | 85,1 | 98,4 | 151 | 220 | 320 |
| EBITDA1 |
- | -57,5 | -120 | -204 | -177 | -101 |
| Operating profit (EBIT)1 |
- | -78,4 | -153 | -225 | -225 | -198 |
| Operating Margin |
- | -92,1% | -155% | -149% | -102% | -61,9% |
| Pre-Tax Profit (EBT)1 |
- | -68,6 | -146 | -245 | -238 | -246 |
| Net income1 |
- | -69,6 | -146 | -244 | -238 | -246 |
| Net margin |
- | -81,8% | -149% | -162% | -108% | -76,8% |
| EPS2 |
- | -1,01 | -1,11 | -1,79 | -1,67 | -1,66 |
| Dividend per Share2 |
- | - | - | - | - | - |
| Last update |
03/29/2019 | 02/26/2020 | 02/24/2021 | 02/25/2021 | 02/25/2021 | 02/25/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
| Net Debt1 |
- | - | - | - | - | - |
| Net Cash position1 |
- | - | - | 303 | 204 | 162 |
| Leverage (Debt / EBITDA) |
- | - | - | 1,48x | 1,15x | 1,60x |
| Free Cash Flow1 |
- | 194 | - | -236 | -155 | -45,0 |
| ROE (Net Profit / Equities) |
- | -44,5% | - | -36,8% | -30,6% | -5,89% |
| Shareholders' equity1 |
- | 156 | - | 664 | 777 | 4 180 |
| ROA (Net Profit / Asset) |
- | -11,2% | - | -25,1% | -18,1% | -5,98% |
| Assets1 |
- | 622 | - | 975 | 1 317 | 4 114 |
| Book Value Per Share2 |
- | 8,26 | - | 4,58 | 3,47 | 3,82 |
| Cash Flow per Share2 |
- | 2,97 | - | -1,84 | -1,51 | - |
| Capex1 |
- | 11,2 | - | 15,0 | 21,0 | 32,0 |
| Capex / Sales |
- | 13,2% | - | 9,96% | 9,54% | 9,98% |
| Last update |
03/29/2019 | 02/26/2020 | 02/24/2021 | 03/02/2021 | 03/02/2021 | 02/25/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
How Moderna executives are cashing in on COVID-19 vaccine stock speculation |
Capitalization (USD) 5 879 239 611 Net sales (USD) 98 382 000 Sales / Employee (USD) 158 170 Free-Float capitalization (USD) 5 445 501 151 Avg. Exchange 20 sessions (USD) 37 721 485 Average Daily Capital Traded 0,64%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
